Characteristics of the European Thoracic Society/American Thoracic Society severe asthma definition as a determinant of future use of biologics/bronchial thermoplasty
Authors:
- Hirono NishiyamaHNHirono Nishiyama
- Yoshihiro KanemitsuYKYoshihiro Kanemitsu
- Kensuke FukumitsuKFKensuke Fukumitsu
- Norihisa TakedaNTNorihisa Takeda
- Ryota KurokawaRKRyota Kurokawa
- Tomoko TajiriTTTomoko Tajiri
- Keima ItoKIKeima Ito
- Jenifer Maries Go YapJYJenifer Maries Go Yap
- Satoshi FukudaSFSatoshi Fukuda
- Takehiro UemuraTUTakehiro Uemura
- Hirotsugu OhkuboHOHirotsugu Ohkubo
- Ken MaenoKMKen Maeno
Open Access
- 1 April 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 12 (2) , e13
Abstract
Background: International guidelines define severe uncontrolled asthma. Biologics or bronchial thermoplasty (Bio/BT) are recommended for such patients. Objectives: To determine which definitions of severe uncontrolled asthma are associated with an additional Bio/BT treatment in patients with severe uncontrolled asthma. Methods: Consecutive 107 asthmatics (including 15 patients for whom Bio/BT was introduced within 3 months after examination), classified as treatment step 4 according to the Global Initiative for Asthma 2015 guideline, were eligible for this analysis. Patients were assessed using the European Thoracic Society/American Thoracic Society (ERS/ATS) severe uncontrolled asthma guideline as defined by these 4 characteristics: poor control (ACT < 20), frequent exacerbations (≥2/yr), admissions (≥1/yr), and airflow limitation (forced expiratory volume in 1 second < 80% of predicted), along with comorbidities, and biomarkers, including blood granulocytes, fractional nitric oxide, and capsaicin cough reflex sensitivity (C-CS). These indices were compared between patients with and without Bio/BT introduction, and multivariate logistic regression analysis was performed to determine the association of the 4 definitions with treatment needs for Bio/BT. Results: Patients who were introduced to Bio/BT had heightened C-CS, heavier smoking history, and a greater prevalence of diabetes mellitus than those without (p < 0.05). Poor asthma control (ACT < 20), frequent exacerbations (≥2/yr), and admissions (≥1/yr) were relevant to the future use of Bio/BT in the multivariate regression analysis. Type 2-related biomarkers including absolute eosinophil counts were higher in patients in the Bio introduction group than in the BT introduction group. Meanwhile, there was no significant difference of the 4 characteristics of severe uncontrolled asthma definition between patients in the Bio and those in the BT groups. Conclusion: Although multiple factors such as treatment cost and asthma phenotypes affect treatment decision-making, the definition of poor asthma control, frequent exacerbations and admission by the ERS/ATS guidelines were important factors for an additional intensive treatment for severe uncontrolled asthma. Trial Registration: UMIN Clinical Trials Registry: UMIN000024734Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (JP20K17219)
This publication has 19 references indexed in Scilit:
- Clinical Burden and Predictors of Asthma Exacerbations in Patients on Guideline-based Steps 4-6 Asthma Therapy in the TENOR CohortThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Asthma phenotypes: the evolution from clinical to molecular approachesNature Medicine, 2012
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e NO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe AsthmaJournal of Allergy and Clinical Immunology, 2010
- Relación del test de control del asma (ACT) con la función pulmonar, niveles de óxido nítrico exhalado y grados de control según la Iniciativa Global para el Asma (GINA)Archivos de Bronconeumología, 2010
- Heterogeneity of asthma according to blood inflammatory patternsThorax, 2009
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004
- Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow upThorax, 2003